WuXi AppTec Posts 34% Profit Jump, Overtakes Lonza, While Sitting on Pentagon's China Military List

The Numbers

WuXi AppTec, the Shanghai-based drug manufacturing giant, posted interim net profit of 11.08 billion yuan ($1.64 billion) for the first half of 2026, up 33.7% from a year earlier, according to the South China Morning Post. That blew past a Bloomberg consensus estimate of 25 analysts who expected 14.5% growth.

Revenue hit CNY 28.9 billion (roughly $4.3 billion), up 38.9% year-over-year, according to BigGo Finance. That figure surpassed Switzerland's Lonza, which posted CHF 3.374 billion (about $3.9 billion) in the same period, marking the first time WuXi has out-earned the company that led the global contract manufacturing market last year.

New order intake grew more than 40% year-on-year, WuXi's chief financial officer Florence Shi said on an August earnings call reported by the South China Morning Post. Chairman and CEO Li Ge credited "strong commercial momentum across various client drug programmes" for the results.

Weight-Loss Drugs Are Doing the Heavy Lifting

The growth engine is WuXi's "TIDES" unit, its peptide and oligonucleotide manufacturing platform built largely around GLP-1 drugs, the class behind Ozempic and Wegovy. TIDES revenue hit CNY 7.26 billion (about $1.1 billion), up 44.3% year-over-year, according to BigGo Finance.

Global drugmakers can't manufacture GLP-1 peptides fast enough on their own, and WuXi has positioned itself as the low-cost, high-capacity contractor of choice. Novo Nordisk and Eli Lilly, the two companies dominating the weight-loss drug market, need contract manufacturers to keep up with demand, and WuXi has grabbed a growing share of that work.

The competitive pressure is real elsewhere too. Samsung Biologics recently agreed to acquire Switzerland's PolyPeptide Group for roughly 2.7 trillion won (about $1.9 billion) just to get into the peptide manufacturing race, according to BigGo Finance. That's a South Korean company spending nearly $2 billion because it doesn't want to be left behind by a Chinese competitor.

The Pentagon Problem

The U.S. Department of Defense added WuXi AppTec to its "1260H List" of Chinese military companies in June, according to BigGo Finance. That's a formal Pentagon designation meant to flag firms the U.S. government believes have ties to China's military-industrial complex.

Being on that list doesn't mean sanctions or a trade ban. It's a list, not an indictment. No criminal charges have been filed against WuXi AppTec, and no broad U.S. export ban currently applies to the company as a result of the 1260H designation alone. But it does create real friction: U.S. defense contractors and companies wary of reputational risk have started distancing themselves from firms on that list, and it feeds into a broader push in Congress, including the BIOSECURE Act efforts, to cut U.S. biotech and pharma companies off from Chinese contract manufacturers over national security concerns.

The legitimate concern driving U.S. policy is whether American drugmakers become dependent on Chinese manufacturing infrastructure for critical medicines, and whether data or biological material generated in partnership with a company the Pentagon has flagged could be compromised. Senator Bill Hagerty and others pushing BIOSECURE-style legislation argue that reliance on Chinese CDMOs creates a supply chain vulnerability similar to what happened with semiconductors, and that the concern isn't hypothetical hostility toward China, it's about not wanting America's drug supply chain controlled by a strategic rival.

Scrutiny Isn't Slowing Them Down

The earnings numbers show the pressure campaign isn't working yet, at least not on WuXi's bottom line. The company raised its full-year revenue guidance to between CNY 58.5 billion and 60.5 billion (roughly $8.5 billion to $9.0 billion), up about 14% from its earlier forecast of CNY 51.3 billion to 53 billion, according to the South China Morning Post.

WuXi is also expanding manufacturing capacity for active pharmaceutical ingredients in Singapore and is reportedly considering multiple other overseas sites, a move that looks like hedging against further U.S. restrictions by diversifying production outside mainland China.

Investors have noticed. WuXi's Hong Kong-listed shares are up about 62% year-to-date as of early August, according to the South China Morning Post — a cumulative gain that dwarfs the Hang Seng Index's roughly 0.48% move on a single trading day in the same period, though the two figures cover different timeframes and aren't a direct apples-to-apples comparison.

What's Unresolved

The open question is whether Washington's political pressure translates into actual market consequences down the road, or whether GLP-1 demand is simply too big and WuXi's manufacturing capacity too cheap and available for U.S. drugmakers to walk away. Lonza's own guidance of 11-12% growth this year suggests it can't match WuXi's pace even without any geopolitical baggage.

If Congress moves forward with BIOSECURE-style restrictions that actually bar U.S. federal contracts or government-funded drug programs from using WuXi, that's the real test. Right now, no such law has passed. Until it does, the Pentagon's list is a warning label, not a wall.